Agilent Technologies Inc (A) Stock News

UWM Holdings Corporation is facing a securities class action lawsuit after its stock plummeted 34% on August 6, 2026, following disclosure of a $603 million hedging loss related to its failed acquisition of Two Harbors Investment Corp. The company allegedly over-hedged its position and failed to adequately disclose the risks. UWM's equity plunged 38% and the company announced a massively dilutive recapitalization plan. The stock has declined approximately 75% since the acquisition announcement in December 2025.

Capricor Therapeutics faces a securities class action lawsuit alleging material misstatements regarding clinical trial data for its lead drug deramiocel. The FDA extended the review period for the drug's Biologics License Application to November 2026 after revealing the company made undisclosed modifications to its statistical analysis plan. The stock crashed 64% on July 27, 2026, when FDA briefing documents revealed the HOPE-3 study failed to meet pre-specified primary endpoints. Investors who purchased shares between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status.

Wix.com (WIX) faces a securities class action lawsuit after its stock plummeted 27% in May 2026 following disappointing Q1 2026 results. The company allegedly misrepresented the competitiveness and performance of its AI products (Base44 and Harmony) while understating associated costs. Operating expenses spiked 46% year-over-year, with non-GAAP S&M expenses surging 88%, causing operating margins to collapse from 21% to 5%. Management acknowledged competitive challenges and product gaps during earnings calls.

Hagens Berman has filed a securities fraud class action lawsuit against HDFC Bank Limited and its executives, alleging the bank concealed a scheme involving approximately Rs 45 crore ($4.7 million USD) in disguised payments to induce state deposits while providing above-market interest rates. The fraudulent practices allegedly violated RBI regulations and the bank's internal policies, resulting in overstated financials. The scheme surfaced following the resignation of the Chairman in March 2026 and an investigative report in May 2026, causing HDFC's stock to decline sharply. The class period covers July 17, 2023 to May 26, 2026, with a lead plaintiff deadline of October 13, 2026.

A securities class action has been filed against PROCEPT BioRobotics for allegedly withholding information about handpiece sales practices. The company allegedly used undisclosed bulk order discount programs to artificially inflate sales by pulling forward orders from future quarters, resulting in excess customer inventory exceeding 10,000 units. The stock declined approximately 48% from August 2025 to February 2026 as the company made successive downward revisions and eventually disclosed the inventory issues.

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly making false and misleading statements about its Phase 3 clinical trial of Fianlimab for melanoma treatment. The company reportedly failed to disclose that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. After initially expressing confidence in the trial, Regeneron altered the trial protocol in November 2025 without timely disclosure and ultimately announced on May 15, 2026 that the trial failed to reach statistical significance, resulting in an $11 billion market cap loss.

H&R Block CEO Curtis Campbell sold 2,833 shares (~$146,324) on August 31, 2026, as a non-discretionary transaction to cover tax withholding obligations from RSU vesting. The sale is not concerning as it's a standard practice. H&R Block recently hit a 52-week high of $58.67, reporting strong FY2026 results with $3.9 billion in revenue (5% YoY growth) and forecasting $4.1-4.2 billion for FY2027, while raising its dividend by 10% for the ninth consecutive year.

DBV Technologies announced the sale of approximately $50 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The company had previously filed an ATM prospectus for up to $150 million in sales. As of August 31, 2026, the company had 314,388,807 total shares outstanding.

Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.

Delta Air Lines (DAL) closed at $78.14, up 2.3% in the latest session, but has depreciated 17.67% over the past month. The company is expected to report EPS of $2.03 (up 18.71% YoY) and revenue of $17.67 billion (up 6% YoY). However, the Zacks Consensus EPS estimate has decreased 4.7% over the last 30 days, and DAL holds a Zacks Rank of #3 (Hold) with a Forward P/E of 12.26, trading at a premium to its industry average. The Transportation-Airline industry ranks in the bottom 18% of all industries.

Broadcom Inc. reported quarterly earnings of $3.32 per share, beating consensus estimates of $3.22, with revenues of $29.59 billion surpassing expectations. The company has beaten EPS estimates four consecutive quarters. However, Broadcom shares have underperformed the S&P 500 year-to-date, gaining 6.8% versus the market's 11.5%. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Ambarella, another semiconductor company, is expected to report results on September 3 with projected earnings of $0.16 per share.

Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company engaged in deceptive health data sharing with advertising platforms like Meta and Snap, and violated billing regulations by charging consumers for prescriptions before medical consultations. The lawsuit, filed by the FTC alongside Utah and Los Angeles County, also accuses Hims of using dark patterns to prevent subscription cancellations. The stock dropped 14.7% ($4.32) on July 29, 2026, erasing over $970 million in market value.

Rosen Law Firm reminds investors in Cogent Communications Holdings, Inc. (NASDAQ: CCOI) of the September 21, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that defendants made materially false statements regarding optical wavelength backlog, customer demand, revenue targets, dividend sustainability, and undisclosed risks related to insider stock pledging activities.

Rosen Law Firm is investigating potential securities claims against PennyMac Financial Services (NYSE: PFSI) for allegedly issuing materially misleading business information. The investigation follows a significant stock price decline of 33.3% on January 30, 2026, after PennyMac reported a substantial drop in servicing segment pretax income from $157.4 million to $37.3 million in Q4 2025.

NetApp reported quarterly earnings of $2.58 per share, beating consensus estimates of $2.13 and representing a 21.13% earnings surprise. The company also exceeded revenue expectations with $2.03 billion, up from $1.56 billion year-over-year. NetApp has outperformed the S&P 500 by 71% year-to-date and holds a Zacks Rank #2 (Buy) rating. UiPath is expected to report results on September 3 with flat earnings expectations of $0.15 per share but 9.9% revenue growth anticipated.

C3.ai reported a quarterly loss of $0.2 per share, beating consensus estimates of $0.26 loss, with a 23.08% earnings surprise. However, revenues declined year-over-year to $52.38 million. The stock has lost 23.3% since the beginning of the year and carries a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Argan (AGX) reported quarterly earnings of $3.76 per share, significantly beating consensus estimates of $2.68 and delivering a 40.3% earnings surprise. The company also surpassed revenue expectations with $383.98 million. However, the stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Meanwhile, Thor Industries (THO) is expected to report a 58.9% year-over-year earnings decline for the same quarter.

The NBA also fined the Los Angeles Clippers $30 million and said the team will forfeit five first-round picks, one in each year in drafts starting in 2029.

A class action lawsuit has been filed against GoDaddy Inc. alleging that the company made materially false and misleading statements between September 3, 2025 and February 24, 2026. The lawsuit claims GoDaddy failed to disclose that its high-intent customer strategy was failing and that promotional discounts on .com domains were negatively impacting bookings and revenue. The stock fell 14.28% on February 25, 2026 following the disclosure of disappointing fourth quarter results.

Zoom announced the appointment of Jeff Epstein, former EVP and CFO of Oracle and current Operating Partner at Bessemer Venture Partners, to its Board of Directors effective immediately. Epstein brings extensive financial and strategic leadership experience in B2B software and AI. Jonathan Chadwick will retire from Zoom's board after nearly ten years of service, effective November 19, 2026.

Baosheng Media Group Holdings Limited (NASDAQ: BAOS) announced that its board of directors has unanimously approved the indefinite postponement of the extraordinary general meeting of shareholders originally scheduled for September 4, 2026. Previously submitted proxy cards will be disregarded, and the company will provide further information regarding any rescheduled meeting in accordance with applicable regulations.

Xilio Therapeutics granted non-qualified stock options to purchase 19,865 shares to two new employees at an exercise price of $8.88 per share on September 1, 2026. The options have a ten-year term with 25% vesting on the first anniversary and the remaining 75% vesting monthly over three years, subject to continued employment.

Byrna Technologies announced the appointment of Matthew McBrady, Ph.D. to its Board of Directors, expanding the board from seven to eight members. McBrady brings extensive experience from his tenure at Axon Enterprise, where he served as a board member and helped guide the company to become the largest personal defense product company with over $50 billion market capitalization. He currently serves as CFO of GoBrands, Inc. (parent company of GoPuff) and previously spent 15 years as a hedge fund and private equity investor.

Entrada Therapeutics granted 61,365 RSUs and options to purchase 19,425 shares to eight newly-hired non-executive employees under its 2025 Inducement Equity Plan, effective September 1, 2026. The options have an exercise price of $7.07 per share, with vesting schedules spanning four years for options and multiple years for RSUs, contingent on continued employment.

Dell Technologies reported Q2 EPS of $7.04, beating consensus estimates by 41.65%, driven by strong AI server demand. The company set multiple revenue records and is on track to double revenue and EPS by 2028. Management projects AI will comprise 75% of data center demand by 2030, with inference workloads expected to grow significantly.

Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026, in New York. Management will participate in a fireside chat on Wednesday, September 16 at 1:50 p.m. ET. The company focuses on developing targeted topicals for chronic inflammatory skin diseases.

Anavex Life Sciences announced it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing outstanding Form 10-Q filings for Q2 and Q3 2026 on August 28, 2026. The clinical-stage biopharmaceutical company, focused on CNS disease treatments, continues to advance its three core clinical development programs with emphasis on Alzheimer's disease.

Acumen Pharmaceuticals announced that management will participate in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and Citi's 2026 Biopharma Back to School Conference on September 10. The company is advancing its lead candidate sabirnetug (ACU193) in Phase 2 trials for early symptomatic Alzheimer's disease and expects to report topline results in late 2026.

Entergy Arkansas said the documents cited by the Arkansas Democrat-Gazette contained "trade secrets" and "highly sensitive protected information."

A class action lawsuit has been filed against Intuit Inc. alleging the company made materially false statements about its competitive advantages and business strength. The lawsuit was triggered after Intuit announced a 17% workforce reduction and reported weak TurboTax revenue growth of only 7% (vs. 8% consensus), causing the stock to plunge 20% on May 21, 2026. Investors who purchased INTU securities between February 25, 2025 and June 1, 2026 can file a lead plaintiff motion by September 8, 2026.